PlainPharmaWatch

CMS Open Payments · Program Year 2024

Medexus Pharma, Inc.

Medexus Pharma, Inc. reported $75,594.05 across General Payments, Research, and Ownership to 57 physicians and teaching hospitals across 57 transactions.

See the rankings → How this is sourced
$75.6K
All-tracks total
57
Transactions
57
Recipients
+$20.9K
General Payments vs PY2023

Medexus Pharma, Inc. reported $75,594.05 across all CMS Open Payments tracks (General + Research + Ownership) to 57 physicians and teaching hospitals in Program Year 2024 - ranking #1254 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $75,594.05, averaging $1.3K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer medexus-pharma-inc Medexus Pharma, Inc.

$75.6K · #1254/1,925 · 0.0% industry · PY2024

  • TOT $75.6K
  • RANK #1254
  • SHARE 0.0%
  • TXN 57
  • RCP 57
  • CAT 3
  • GEN $75.6K
  • ΔGEN +$20.9K
  • TOP1 19.5%
  • PY 2024

Volume peers

Nearest volume peer: Pinnacle Biologics, Inc ($75.4K)

Kuros Biosciences AG$76.3KAdvanced Sterilization Produ…$76.1KClinician's Choice Dental Pr…$76.0KMedexus Pharma, Inc. (this)$75.6KPinnacle Biologics, Inc$75.4K
All-tracks payment totals near Medexus Pharma, Inc. (CMS Open Payments PY2024)

Medexus Pharma, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Medexus Pharma, Inc.'s CMS-reported General Payments increased by $20.9K (+38.3%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: MEDEXUS PHARMA, INC.PY2023: MEDEXUS PHARMA, INC.PY2024: Medexus Pharma, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$54.6KPY2024$75.6K
PY2023
$54,646.89
PY2024
$75,594.05

What the Data Shows for Medexus Pharma, Inc.

$75,594.05: that is what Medexus Pharma, Inc. reported in payments to 57 physicians and teaching hospitals during Program Year 2024, spread across 57 transactions ($1.3K per transaction, $1.3K per recipient). The company sits at rank #1254 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

30 transactions worth $73.5K make "Consulting Fee" the top general-payment category in the 3-category breakdown below, 97.3% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 3 types of general payments, Medexus Pharma, Inc.'s largest category was "Consulting Fee" at $73.5K - 97.3% of General Payments.

How Medexus Pharma, Inc. divides its payments

General-payment categories, ordered by reported total

1. Consulting Fee$73.5K2. Food and Beverage$1.3K3. Travel and Lodging$776.80
Payment Type Amount Transactions
Consulting Fee $73.5K 30
Food and Beverage $1.3K 26
Travel and Lodging $776.80 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $31,821.76 (42.1%) of $75,594.05 in this company's General Payments records across 48 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Medexus Pharma, Inc.

The five named recipients with the highest reported General Payments from this company

Randy D'amico$14.7KFilippo Milano$8.2KEneida Nemecek$3.4KAndromachi Scaradavou$3.4KSagar Patel$2.1K
  1. 1

    Randy D'amico

    $14,723.97 across 6 reported transactions

  2. 2

    Filippo Milano

    $8,197.79 across 5 reported transactions

  3. 3

    Eneida Nemecek

    $3,400.00 across 1 reported transactions

  4. 4

    Andromachi Scaradavou

    $3,400.00 across 1 reported transactions

  5. 5

    Sagar Patel

    $2,100.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Medexus Pharma, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Medexus Pharma, Inc..

Neurent Medical Limited

HHI 699

Nordic Pharma, Inc.

HHI 700

BK Medical Holding Company Inc.

HHI 693

HEMA Biologics, LLC

HHI 691

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Medexus Pharma, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Medexus Pharma, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.